This site uses cookies to store information on your computer. Learn more x

Consensus Figures

A number of international financial analysts cover DSM. The most recent consensus figures – provided by Vara Research – are detailed below. The figures are based on the estimates given by the banks that were approached by Vara Research.

Analysts' consensus Q2 2018 and FY 2018 as at 11 June 2018

  Q2 2017 FY 2017 Q1 2018 Q2 2018 E FY 2018 E
Total Sales          
  Number of Estimates       18 19
  Highest       2,453 9,607
  Consensus 2,161 8,632 2,435 2,393 9,298
  Median       2,406 9,317
  Lowest       2,251 8,931
Total adjusted EBITDA          
  Number of Estimates       18 19
  Highest       583 1,901
  Consensus 376 1,445 538 511 1,830
  Median       505 1,824
  Lowest       488 1,782
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       15 15
  Highest       165 330
  Consensus - - 165 120 289
  Median       115 285
  Lowest       100 265
           
Total adjusted EBIT          
  Number of Estimates       16 19
  Highest       466 1,436
  Consensus 256 957 423 391 1,341
  Median       386 1,330
  Lowest       367 1,252
Nutrition, Sales          
  Number of Estimates       18 19
  Highest       1,651 6,378
  Consensus 1,380 5,579 1,650 1,586 6,122
  Median       1,597 6,152
  Lowest       1,463 5,750
Nutrition, adj. EBITDA          
  Number of Estimates       18 19
  Highest       481 1,503
  Consensus 271 1,053 442 401 1,412
  Median       399 1,407
  Lowest       376 1,356
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       15 15
  Highest       165 330
  Consensus - - 165 120 289
  Median       115 285
  Lowest       100 265
Nutrition, adj. EBIT          
  Number of Estimates       15 15
  Highest       410 1,215
  Consensus 198 770 370 331 1,124
  Median       330 1,128
  Lowest       303 1,061
Materials, Sales          
  Number of Estimates       18 19
  Highest       783 3,002
  Consensus 725 2,825 738 750 2,949
  Median       755 2,951
  Lowest       709 2,869
Materials, adj. EBITDA          
  Number of Estimates       18 19
  Highest       145 534
  Consensus 128 488 126 133 514
  Median       133 515
  Lowest       125 492
Materials, adj. EBIT          
  Number of Estimates       15 15
  Highest       114 407
  Consensus 96 361 95 101 385
  Median       100 385
  Lowest       93 371
Innovation Center, Sales          
  Number of Estimates       17 18
  Highest       46 186
  Consensus 41 169 36 41 169
  Median       42 167
  Lowest       36 144
Innovation Center, adj. EBITDA          
  Number of Estimates       17 18
  Highest       6 22
  Consensus 0 9 -1 2 9
  Median       2 9
  Lowest       -1 -1
Innovation Center, adj. EBIT          
  Number of Estimates       15 15
  Highest       1 -8
  Consensus -7 -30 -6 -5 -19
  Median       -6 -18
  Lowest       -8 -29
Corporate Activities, Sales          
  Number of Estimates       17 18
  Highest       22 77
  Consensus 15 59 11 16 60
  Median       16 59
  Lowest       11 50
Corporate Activities, adj. EBITDA          
  Number of Estimates       17 18
  Highest       -22 -90
  Consensus -23 -105 -29 -26 -105
  Median       -25 -105
  Lowest       -29 -116
Corporate Activities, adj. EBIT          
  Number of Estimates       15 15
  Highest       -32 -128
  Consensus -31 -144 -36 -35 -142
  Median       -36 -144
  Lowest       -39 -150
Profit for the period, before exceptional items - Cont. Ops.          
  Number of Estimates       16 19
  Highest       374.0 1,141.0
  Consensus 175.0 706.0 337.0 292.6 1,042.4
  Median       291.3 1,038.0
  Lowest       180.0 895.0
Net EPS before exceptional items - Cont. Ops.          
  Number of Estimates       16 19
  Highest       2.13 6.47
  Consensus 0.98 3.92 1.91 1.66 5.87
  Median       1.65 5.87
  Lowest       1.03 5.12

Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.